REIT - Healthcare Facilities
Compare Stocks
4 / 10Stock Comparison
GMRE vs PLYM vs STAG vs CHCT
Revenue, margins, valuation, and 5-year total return — side by side.
REIT - Industrial
REIT - Industrial
REIT - Healthcare Facilities
GMRE vs PLYM vs STAG vs CHCT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | REIT - Healthcare Facilities | REIT - Industrial | REIT - Industrial | REIT - Healthcare Facilities |
| Market Cap | $94M | $979M | $7.39B | $505M |
| Revenue (TTM) | $148M | $192M | $864M | $122M |
| Net Income (TTM) | $2M | $93M | $244M | $6M |
| Gross Margin | 68.8% | 69.7% | 61.8% | 62.8% |
| Operating Margin | 24.9% | 17.3% | 37.9% | 31.3% |
| Forward P/E | 595.7x | 7.1x | 38.1x | 37.6x |
| Total Debt | $654M | $646M | $3.29B | $536M |
| Cash & Equiv. | $7M | $18M | $15M | $3M |
GMRE vs PLYM vs STAG vs CHCT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| Global Medical REIT… (GMRE) | 100 | 66.7 | -33.3% |
| Plymouth Industrial… (PLYM) | 100 | 147.8 | +47.8% |
| STAG Industrial, In… (STAG) | 100 | 145.8 | +45.8% |
| Community Healthcar… (CHCT) | 100 | 46.9 | -53.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GMRE vs PLYM vs STAG vs CHCT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GMRE is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 5 yrs, beta 0.48, yield 63.5%
- 308.1% 10Y total return vs STAG's 147.9%
- 63.5% yield, 5-year raise streak, vs CHCT's 11.3%
PLYM carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 0.20, current ratio 0.42x
- Beta 0.20, yield 4.4%, current ratio 0.42x
- Lower P/E (7.1x vs 38.1x)
- 48.5% margin vs GMRE's 1.7%
STAG is the clearest fit if your priority is growth exposure.
- Rev growth 10.1%, EPS growth 40.4%, 3Y rev CAGR 8.7%
- 10.1% FFO/revenue growth vs GMRE's -1.8%
CHCT lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.1% FFO/revenue growth vs GMRE's -1.8% | |
| Value | Lower P/E (7.1x vs 38.1x) | |
| Quality / Margins | 48.5% margin vs GMRE's 1.7% | |
| Stability / Safety | Beta 0.20 vs CHCT's 0.60, lower leverage | |
| Dividends | 63.5% yield, 5-year raise streak, vs CHCT's 11.3% | |
| Momentum (1Y) | +45.5% vs GMRE's +0.1% | |
| Efficiency (ROA) | 5.9% ROA vs GMRE's 0.2%, ROIC 2.1% vs 2.0% |
GMRE vs PLYM vs STAG vs CHCT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
GMRE vs PLYM vs STAG vs CHCT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GMRE leads in 1 of 6 categories
PLYM leads 0 • STAG leads 0 • CHCT leads 0 • 5 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — PLYM and STAG each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
STAG is the larger business by revenue, generating $864M annually — 7.1x CHCT's $122M. PLYM is the more profitable business, keeping 48.5% of every revenue dollar as net income compared to GMRE's 1.7%. On growth, GMRE holds the edge at +18.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $148M | $192M | $864M | $122M |
| EBITDAEarnings before interest/tax | $95M | $116M | $634M | $82M |
| Net IncomeAfter-tax profit | $2M | $93M | $244M | $6M |
| Free Cash FlowCash after capex | $19M | $95M | $443M | $60M |
| Gross MarginGross profit ÷ Revenue | +68.8% | +69.7% | +61.8% | +62.8% |
| Operating MarginEBIT ÷ Revenue | +24.9% | +17.3% | +37.9% | +31.3% |
| Net MarginNet income ÷ Revenue | +1.7% | +48.5% | +28.3% | +5.0% |
| FCF MarginFCF ÷ Revenue | +12.6% | +49.4% | +51.2% | +49.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.7% | -1.4% | +9.1% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -166.2% | -2.5% | -34.7% | +124.4% |
Valuation Metrics
GMRE leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 7.1x trailing earnings, PLYM trades at a 97% valuation discount to CHCT's 228.4x P/E. On an enterprise value basis, GMRE's 8.3x EV/EBITDA is more attractive than STAG's 17.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $94M | $979M | $7.4B | $505M |
| Enterprise ValueMkt cap + debt − cash | $741M | $1.6B | $10.7B | $1.0B |
| Trailing P/EPrice ÷ TTM EPS | 115.29x | 7.11x | 26.48x | 228.42x |
| Forward P/EPrice ÷ next-FY EPS est. | 595.67x | — | 38.07x | 37.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 13.00x | — |
| EV / EBITDAEnterprise value multiple | 8.35x | 13.32x | 17.20x | 16.27x |
| Price / SalesMarket cap ÷ Revenue | 0.68x | 4.94x | 8.75x | 4.17x |
| Price / BookPrice ÷ Book value/share | 0.17x | 1.69x | 1.98x | 1.11x |
| Price / FCFMarket cap ÷ FCF | — | 10.19x | 18.40x | 8.95x |
Profitability & Efficiency
Evenly matched — PLYM and STAG each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
PLYM delivers a 16.8% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $0 for GMRE. STAG carries lower financial leverage with a 0.90x debt-to-equity ratio, signaling a more conservative balance sheet compared to CHCT's 1.25x. On the Piotroski fundamental quality scale (0–9), PLYM scores 7/9 vs GMRE's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +0.5% | +16.8% | +6.8% | +1.4% |
| ROA (TTM)Return on assets | +0.2% | +5.9% | +3.5% | +0.6% |
| ROICReturn on invested capital | +2.0% | +2.1% | +3.5% | +1.6% |
| ROCEReturn on capital employed | +5.3% | +2.8% | +4.9% | +2.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 5 | 5 |
| Debt / EquityFinancial leverage | 1.18x | 1.10x | 0.90x | 1.25x |
| Net DebtTotal debt minus cash | $647M | $628M | $3.3B | $533M |
| Cash & Equiv.Liquid assets | $7M | $18M | $15M | $3M |
| Total DebtShort + long-term debt | $654M | $646M | $3.3B | $536M |
| Interest CoverageEBIT ÷ Interest expense | 1.14x | 0.97x | 3.04x | 1.15x |
Total Returns (Dividends Reinvested)
Evenly matched — PLYM and STAG each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PLYM five years ago would be worth $13,852 today (with dividends reinvested), compared to $5,441 for CHCT. Over the past 12 months, PLYM leads with a +45.5% total return vs GMRE's +0.1%. The 3-year compound annual growth rate (CAGR) favors STAG at 6.8% vs CHCT's -13.9% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.9% | +0.5% | +5.8% | +11.2% |
| 1-Year ReturnPast 12 months | +0.1% | +45.5% | +19.8% | +14.5% |
| 3-Year ReturnCumulative with dividends | +5.6% | +15.1% | +21.8% | -36.1% |
| 5-Year ReturnCumulative with dividends | -21.4% | +38.5% | +26.4% | -45.6% |
| 10-Year ReturnCumulative with dividends | +308.1% | +68.9% | +147.9% | +83.9% |
| CAGR (3Y)Annualised 3-year return | +1.8% | +4.8% | +6.8% | -13.9% |
Risk & Volatility
Evenly matched — PLYM and CHCT each lead in 1 of 2 comparable metrics.
Risk & Volatility
PLYM is the less volatile stock with a 0.20 beta — it tends to amplify market swings less than CHCT's 0.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CHCT currently trades 97.0% from its 52-week high vs GMRE's 89.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.48x | 0.20x | 0.55x | 0.60x |
| 52-Week HighHighest price in past year | $39.93 | $22.74 | $39.99 | $18.22 |
| 52-Week LowLowest price in past year | $29.05 | $14.05 | $33.19 | $13.23 |
| % of 52W HighCurrent price vs 52-week peak | +89.5% | +96.7% | +96.7% | +97.0% |
| RSI (14)Momentum oscillator 0–100 | 52.7 | 56.8 | 51.5 | 56.9 |
| Avg Volume (50D)Average daily shares traded | 130K | 132K | 1.2M | 228K |
Analyst Outlook
Evenly matched — GMRE and CHCT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: GMRE as "Buy", PLYM as "Hold", STAG as "Buy", CHCT as "Hold". Consensus price targets imply 17.7% upside for STAG (target: $46) vs -4.5% for PLYM (target: $21). For income investors, GMRE offers the higher dividend yield at 63.51% vs STAG's 3.90%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | $40.00 | $21.00 | $45.50 | $18.50 |
| # AnalystsCovering analysts | 22 | 16 | 21 | 16 |
| Dividend YieldAnnual dividend ÷ price | +63.5% | +4.4% | +3.9% | +11.3% |
| Dividend StreakConsecutive years of raises | 5 | 1 | 2 | 11 |
| Dividend / ShareAnnual DPS | $22.70 | $0.97 | $1.51 | $2.00 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | 0.0% | +0.4% |
GMRE leads in 1 of 6 categories — strongest in Valuation Metrics. 5 categories are tied.
GMRE vs PLYM vs STAG vs CHCT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GMRE or PLYM or STAG or CHCT a better buy right now?
For growth investors, STAG Industrial, Inc.
(STAG) is the stronger pick with 10. 1% revenue growth year-over-year, versus -1. 8% for Global Medical REIT Inc. (GMRE). Plymouth Industrial REIT, Inc. (PLYM) offers the better valuation at 7. 1x trailing P/E, making it the more compelling value choice. Analysts rate Global Medical REIT Inc. (GMRE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GMRE or PLYM or STAG or CHCT?
On trailing P/E, Plymouth Industrial REIT, Inc.
(PLYM) is the cheapest at 7. 1x versus Community Healthcare Trust Incorporated at 228. 4x. On forward P/E, Community Healthcare Trust Incorporated is actually cheaper at 37. 6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — GMRE or PLYM or STAG or CHCT?
Over the past 5 years, Plymouth Industrial REIT, Inc.
(PLYM) delivered a total return of +38. 5%, compared to -45. 6% for Community Healthcare Trust Incorporated (CHCT). Over 10 years, the gap is even starker: GMRE returned +308. 1% versus PLYM's +68. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GMRE or PLYM or STAG or CHCT?
By beta (market sensitivity over 5 years), Plymouth Industrial REIT, Inc.
(PLYM) is the lower-risk stock at 0. 20β versus Community Healthcare Trust Incorporated's 0. 60β — meaning CHCT is approximately 194% more volatile than PLYM relative to the S&P 500. On balance sheet safety, STAG Industrial, Inc. (STAG) carries a lower debt/equity ratio of 90% versus 125% for Community Healthcare Trust Incorporated — giving it more financial flexibility in a downturn.
05Which is growing faster — GMRE or PLYM or STAG or CHCT?
By revenue growth (latest reported year), STAG Industrial, Inc.
(STAG) is pulling ahead at 10. 1% versus -1. 8% for Global Medical REIT Inc. (GMRE). On earnings-per-share growth, the picture is similar: Plymouth Industrial REIT, Inc. grew EPS 1445% year-over-year, compared to -94. 6% for Global Medical REIT Inc.. Over a 3-year CAGR, PLYM leads at 12. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GMRE or PLYM or STAG or CHCT?
Plymouth Industrial REIT, Inc.
(PLYM) is the more profitable company, earning 70. 2% net margin versus 4. 2% for Community Healthcare Trust Incorporated — meaning it keeps 70. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: STAG leads at 37. 7% versus 16. 7% for CHCT. At the gross margin level — before operating expenses — GMRE leads at 78. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GMRE or PLYM or STAG or CHCT more undervalued right now?
On forward earnings alone, Community Healthcare Trust Incorporated (CHCT) trades at 37.
6x forward P/E versus 595. 7x for Global Medical REIT Inc. — 558. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STAG: 17. 7% to $45. 50.
08Which pays a better dividend — GMRE or PLYM or STAG or CHCT?
All stocks in this comparison pay dividends.
Global Medical REIT Inc. (GMRE) offers the highest yield at 63. 5%, versus 3. 9% for STAG Industrial, Inc. (STAG).
09Is GMRE or PLYM or STAG or CHCT better for a retirement portfolio?
For long-horizon retirement investors, Plymouth Industrial REIT, Inc.
(PLYM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 20), 4. 4% yield). Both have compounded well over 10 years (PLYM: +68. 9%, CHCT: +83. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GMRE and PLYM and STAG and CHCT?
Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: GMRE is a small-cap income-oriented stock; PLYM is a small-cap deep-value stock; STAG is a small-cap income-oriented stock; CHCT is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.